FIGURE 8.

Aidi injection and GP combination in NSCLC, Aidi's value in adjuvant chemotherapy may be broad-spectrum, not just for some regimens. The Aidi and GP combination may show a good short-term response, antitumor immunity, and safety level in NSCLC. Aidi may be more suitable for patients with a KPS score ≥60 or AST ≥3 months, and first-treated or elderly patients. Aidi (50 ml/day, 7–14 days/cycle for one and two cycles) with GEM (1000 mg/m²) and DDP (20–30 mg/m² or 40–50 mg/m²) may be an optimal regimen. Note: AST, anticipated survival time; DCR, disease control rate; DDP, cisplatin; GEM, Gemcitabine; KPS: KPS, Karnofsky Performance Status; NSCLC, non-small cell lung cancer; ORR, objective response rate.